Chemomab Therapeutics (CMMB) AI Stock Analysis

• Market Cap: $21.69M
• Dividend Yield: N/A
• Average Volume (3M): 170.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: 57.93%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 18,856,611
• 10 Day Avg. Volume: 82,349
• 30 Day Avg. Volume: 170,421
• PEG Ratio: -0.26
• Price to Book (P/B): 20.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.63
• Enterprise Value/Market Cap: 34.81
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -28.07K
• Enterprise Value/Ebitda: -11.34
• 1Y Price Target: $8.50
• Price Target Upside: 632.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 33 Underperform
• Price Target: ―

Chemomab Therapeutics' overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company's future performance heavily relies on its ability to develop and commercialize products successfully.

Positive Factors

Regulatory Approval

Chemomab announced positive feedback from the FDA following its End-of-Phase 2 and Type C meetings to support advancing nebokitug into Phase 3 development for primary sclerosing cholangitis.

Strategic Partnerships

Chemomab is in active strategic partnering discussions to advance the program into Phase 3, which is expected to bring the asset forward significantly.

Study Design

Nebokitug's single pivotal Phase 3 study is expected to not require a liver biopsy, using a clinical events-based endpoint, making it less costly and easier to enroll.

Negative Factors

Cost Considerations

Avoiding a biopsy endpoint was a key objective of Chemomab's regulatory interactions. Biopsy endpoints complicate enrollment and add considerable additional cost.

Development Risks

Conducting non-clinical fetal and embryo developmental toxicology testing in parallel with Phase 3 could present additional challenges in the approval process.

Chemomab Therapeutics Business Overview & Revenue Model

Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

How the Company Makes Money

Chemomab Therapeutics generates revenue primarily through strategic partnerships, collaborations, and potentially from licensing agreements related to its proprietary technologies and drug candidates. As a clinical-stage company, it may also receive milestone payments, research funding, and royalties from partnerships with larger pharmaceutical companies. These collaborations can provide financial support for ongoing research and development activities, helping the company advance its pipeline towards commercialization. Currently, the company does not generate revenue from product sales as its drug candidates are still undergoing clinical trials.

Chemomab Therapeutics Financial Statement Overview

Summary

Chemomab Therapeutics is in a challenging financial position characterized by ongoing losses and zero revenue. While its balance sheet reveals low leverage and a strong equity base, the lack of any income-generating operations and negative cash flow highlight significant risks. The company's future depends heavily on its ability to commercialize products and generate revenue.

Income Statement

Chemomab Therapeutics has consistently reported zero revenue over the past years, indicating a lack of commercial operations or marketable products. Despite reducing its losses in recent years, the company's net profit margin remains negative, reflecting continued operational challenges and high costs relative to non-existent revenue.

Balance Sheet

The company's balance sheet shows a strong equity position relative to its total assets, indicating financial stability and low leverage. However, the absence of revenue and ongoing losses pose a risk to long-term sustainability. The debt-to-equity ratio is low, suggesting limited reliance on debt financing.

Cash Flow

Chemomab's cash flow statement demonstrates negative operating cash flow, which is a concern, especially with no revenue generation. The company has managed its cash burn through financing activities, but this is not sustainable in the long run without positive cash flow from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-66.83K	-57.77K	-34.02K	-80.00K
EBITDA	-14.67K	-25.39M	-28.48M	-12.33M	-5.95M
Net Income	-13.95K	-24.22M	-27.65M	-12.48M	-5.95M
Balance Sheet
Total Assets	16.96M	22.15M	43.06M	64.35M	12.48M
Cash, Cash Equivalents and Short-Term Investments	14.27M	19.78M	39.89M	61.16M	11.70M
Total Debt	324.00K	392.00K	214.00K	343.00K	428.00K
Total Liabilities	3.43M	5.15M	6.84M	2.89M	1.67M
Stockholders Equity	13.54M	17.00M	36.22M	61.47M	10.80M
Cash Flow
Free Cash Flow	-15.39M	-23.61M	-20.44M	-12.61M	-5.28M
Operating Cash Flow	-15.46M	-23.61M	-20.37M	-12.37M	-5.24M
Investing Cash Flow	2.30M	15.88M	19.53M	-45.19M	-62.00K
Financing Cash Flow	9.87M	3.50M	-808.00K	61.07M	4.75M

Chemomab Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMMB, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.27, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMMB.

Chemomab Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
LGVN	47 Neutral	$24.92M	―	-167.57%	―	127.51%	71.16%
PASG	44 Neutral	$26.91M	―	-83.73%	―	―	42.39%
QTTB	41 Neutral	$16.59M	―	-267.20%	―	-100.00%	91.45%
CALC	39 Underperform	$22.49M	―	-134.15%	―	―	95.48%
TENX	36 Underperform	$23.85M	―	-39.78%	―	―	84.17%
CMMB	33 Underperform	$21.69M	―	-112.99%	―	―	57.93%